Selected research
Industry Research
Skin Cancer Diagnostics Therapeutics Industry Research Report 2026
Market perspective
The global Skin Cancer Diagnostics Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Skin Cancer Diagnostics Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Skin Cancer Diagnostics Therapeutics market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Skin Cancer Diagnostics Therapeutics market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Skin Cancer Diagnostics Therapeutics include Abbott, Merck & Co., Inc., GlaxoSmithKline, Amgen, Sun Pharmaceutical Industries Ltd., Qiagen NV, Novartis AG, F. Hoffmann-La Roche Ltd and Bristol-Myers Squibb Company and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Skin Cancer Diagnostics Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Skin Cancer Diagnostics Therapeutics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Skin Cancer Diagnostics Therapeutics Market by Company
Abbott
Merck & Co., Inc.
GlaxoSmithKline
Amgen
Sun Pharmaceutical Industries Ltd.
Qiagen NV
Novartis AG
F. Hoffmann-La Roche Ltd
Bristol-Myers Squibb Company
AstraZeneca PLC
Skin Cancer Diagnostics Therapeutics Segment by Type
Melanoma
Non-melanoma
Skin Cancer Diagnostics Therapeutics Segment by Application
Hospital
Clinic
Other
Skin Cancer Diagnostics Therapeutics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Skin Cancer Diagnostics Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Skin Cancer Diagnostics Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Skin Cancer Diagnostics Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Skin Cancer Diagnostics Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Melanoma
- Non-melanoma
Applications
- Hospital
- Clinic
- Other
Companies covered
- Abbott
- Merck & Co., Inc.
- GlaxoSmithKline
- Amgen
- Sun Pharmaceutical Industries Ltd.
- Qiagen NV
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- AstraZeneca PLC
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Skin Cancer Diagnostics Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Melanoma
- 2.2.3 Non-melanoma
- 2.3 Skin Cancer Diagnostics Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Skin Cancer Diagnostics Therapeutics Breakdown Data by Type
- 3.1 Global Skin Cancer Diagnostics Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global Skin Cancer Diagnostics Therapeutics Forecasted Market Size by Type (2027-2032)
4 Skin Cancer Diagnostics Therapeutics Breakdown Data by Application
- 4.1 Global Skin Cancer Diagnostics Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global Skin Cancer Diagnostics Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Skin Cancer Diagnostics Therapeutics Market Perspective (2021-2032)
- 5.2 Global Skin Cancer Diagnostics Therapeutics Growth Trends by Region
- 5.2.1 Global Skin Cancer Diagnostics Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Skin Cancer Diagnostics Therapeutics Historic Market Size by Region (2021-2026)
- 5.2.3 Skin Cancer Diagnostics Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 Skin Cancer Diagnostics Therapeutics Market Dynamics
- 5.3.1 Skin Cancer Diagnostics Therapeutics Industry Trends
- 5.3.2 Skin Cancer Diagnostics Therapeutics Market Drivers
- 5.3.3 Skin Cancer Diagnostics Therapeutics Market Challenges
- 5.3.4 Skin Cancer Diagnostics Therapeutics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Skin Cancer Diagnostics Therapeutics Players by Revenue
- 6.1.1 Global Top Skin Cancer Diagnostics Therapeutics Players by Revenue (2021-2026)
- 6.1.2 Global Skin Cancer Diagnostics Therapeutics Revenue Market Share by Players (2021-2026)
- 6.2 Global Skin Cancer Diagnostics Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Skin Cancer Diagnostics Therapeutics Head Office and Area Served
- 6.4 Global Skin Cancer Diagnostics Therapeutics Players, Product Type & Application
- 6.5 Global Skin Cancer Diagnostics Therapeutics Manufacturers Established Date
- 6.6 Global Skin Cancer Diagnostics Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Skin Cancer Diagnostics Therapeutics Market Size (2021-2032)
- 7.2 North America Skin Cancer Diagnostics Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Skin Cancer Diagnostics Therapeutics Market Size by Country (2021-2026)
- 7.4 North America Skin Cancer Diagnostics Therapeutics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Skin Cancer Diagnostics Therapeutics Market Size (2021-2032)
- 8.2 Europe Skin Cancer Diagnostics Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Skin Cancer Diagnostics Therapeutics Market Size by Country (2021-2026)
- 8.4 Europe Skin Cancer Diagnostics Therapeutics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Skin Cancer Diagnostics Therapeutics Market Size (2021-2032)
- 9.2 Asia-Pacific Skin Cancer Diagnostics Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Skin Cancer Diagnostics Therapeutics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Skin Cancer Diagnostics Therapeutics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Skin Cancer Diagnostics Therapeutics Market Size (2021-2032)
- 10.2 South America Skin Cancer Diagnostics Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Skin Cancer Diagnostics Therapeutics Market Size by Country (2021-2026)
- 10.4 South America Skin Cancer Diagnostics Therapeutics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Skin Cancer Diagnostics Therapeutics Market Size (2021-2032)
- 11.2 Middle East & Africa Skin Cancer Diagnostics Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Skin Cancer Diagnostics Therapeutics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Skin Cancer Diagnostics Therapeutics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Abbott
- 12.1.1 Abbott Company Information
- 12.1.2 Abbott Business Overview
- 12.1.3 Abbott Revenue in Skin Cancer Diagnostics Therapeutics Business (2021-2026)
- 12.1.4 Abbott Skin Cancer Diagnostics Therapeutics Product Portfolio
- 12.1.5 Abbott Recent Developments
- 12.2 Merck & Co., Inc.
- 12.2.1 Merck & Co., Inc. Company Information
- 12.2.2 Merck & Co., Inc. Business Overview
- 12.2.3 Merck & Co., Inc. Revenue in Skin Cancer Diagnostics Therapeutics Business (2021-2026)
- 12.2.4 Merck & Co., Inc. Skin Cancer Diagnostics Therapeutics Product Portfolio
- 12.2.5 Merck & Co., Inc. Recent Developments
- 12.3 GlaxoSmithKline
- 12.3.1 GlaxoSmithKline Company Information
- 12.3.2 GlaxoSmithKline Business Overview
- 12.3.3 GlaxoSmithKline Revenue in Skin Cancer Diagnostics Therapeutics Business (2021-2026)
- 12.3.4 GlaxoSmithKline Skin Cancer Diagnostics Therapeutics Product Portfolio
- 12.3.5 GlaxoSmithKline Recent Developments
- 12.4 Amgen
- 12.4.1 Amgen Company Information
- 12.4.2 Amgen Business Overview
- 12.4.3 Amgen Revenue in Skin Cancer Diagnostics Therapeutics Business (2021-2026)
- 12.4.4 Amgen Skin Cancer Diagnostics Therapeutics Product Portfolio
- 12.4.5 Amgen Recent Developments
- 12.5 Sun Pharmaceutical Industries Ltd.
- 12.5.1 Sun Pharmaceutical Industries Ltd. Company Information
- 12.5.2 Sun Pharmaceutical Industries Ltd. Business Overview
- 12.5.3 Sun Pharmaceutical Industries Ltd. Revenue in Skin Cancer Diagnostics Therapeutics Business (2021-2026)
- 12.5.4 Sun Pharmaceutical Industries Ltd. Skin Cancer Diagnostics Therapeutics Product Portfolio
- 12.5.5 Sun Pharmaceutical Industries Ltd. Recent Developments
- 12.6 Qiagen NV
- 12.6.1 Qiagen NV Company Information
- 12.6.2 Qiagen NV Business Overview
- 12.6.3 Qiagen NV Revenue in Skin Cancer Diagnostics Therapeutics Business (2021-2026)
- 12.6.4 Qiagen NV Skin Cancer Diagnostics Therapeutics Product Portfolio
- 12.6.5 Qiagen NV Recent Developments
- 12.7 Novartis AG
- 12.7.1 Novartis AG Company Information
- 12.7.2 Novartis AG Business Overview
- 12.7.3 Novartis AG Revenue in Skin Cancer Diagnostics Therapeutics Business (2021-2026)
- 12.7.4 Novartis AG Skin Cancer Diagnostics Therapeutics Product Portfolio
- 12.7.5 Novartis AG Recent Developments
- 12.8 F. Hoffmann-La Roche Ltd
- 12.8.1 F. Hoffmann-La Roche Ltd Company Information
- 12.8.2 F. Hoffmann-La Roche Ltd Business Overview
- 12.8.3 F. Hoffmann-La Roche Ltd Revenue in Skin Cancer Diagnostics Therapeutics Business (2021-2026)
- 12.8.4 F. Hoffmann-La Roche Ltd Skin Cancer Diagnostics Therapeutics Product Portfolio
- 12.8.5 F. Hoffmann-La Roche Ltd Recent Developments
- 12.9 Bristol-Myers Squibb Company
- 12.9.1 Bristol-Myers Squibb Company Company Information
- 12.9.2 Bristol-Myers Squibb Company Business Overview
- 12.9.3 Bristol-Myers Squibb Company Revenue in Skin Cancer Diagnostics Therapeutics Business (2021-2026)
- 12.9.4 Bristol-Myers Squibb Company Skin Cancer Diagnostics Therapeutics Product Portfolio
- 12.9.5 Bristol-Myers Squibb Company Recent Developments
- 12.10 AstraZeneca PLC
- 12.10.1 AstraZeneca PLC Company Information
- 12.10.2 AstraZeneca PLC Business Overview
- 12.10.3 AstraZeneca PLC Revenue in Skin Cancer Diagnostics Therapeutics Business (2021-2026)
- 12.10.4 AstraZeneca PLC Skin Cancer Diagnostics Therapeutics Product Portfolio
- 12.10.5 AstraZeneca PLC Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst